Ogremorphin has been shown to block GPR68-dependent migration and metastasis of cancer cells, and more recent work indicates that GPR68 inhibition using Ogremorphin or related compounds can induce ferroptosis and radiosensitization in glioblastoma and other tumor models [59,60,61]. The gene discussed is GPR68; the disease is cancer.